A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
Clinical trial NCT00324220 · COMPLETED
Trial details
- NCT number
- NCT00324220
- Sponsor
- Mirati Therapeutics Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2006-01-01
- Primary completion
- 2008-11-01
- Enrollment
- 66
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.